Alivus Life Sciences Limited — Investor Meet, 13-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Alivus Life Sciences posted strong Q2 FY26 revenue of INR 588 Cr (+16% YoY) and H1 revenue of INR 1,190 Cr (+8.6% YoY). Non-GPL business grew 39.7%, fueling broad-based growth. Gross margin hit 57.7% and EBITDA margin 33% in Q2, driven by new launches and cost efficiency. While CDMO and GPL segments were soft in H1, management anticipates a significant rebound in H2 FY26, reaffirming high single-digit FY26 revenue growth and sustained 30% margins. Capex is lower than planned for FY26 but expansion projects remain on schedule. The company is net debt-free with INR 653 Cr cash and is confident in its strategic focus on 'API Plus' and robust pipeline.